Summit Therapeutics Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Summit Therapeutics Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2017 to 2023.
  • Summit Therapeutics Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $485K, a 99.4% decline year-over-year.
  • Summit Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $86.5M, a 86.1% decline from 2022.
  • Summit Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $620M, a 696% increase from 2021.
  • Summit Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $77.9M, a 54.1% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $86.5M -$534M -86.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-20
2022 $620M +$542M +696% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-20
2021 $77.9M +$27.4M +54.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 $50.6M +$1.05M +2.11% Jan 1, 2020 Dec 31, 2020 10-K/A 2022-12-21
2019 $49.5M +$5M +11.2% Feb 1, 2019 Dec 31, 2019 10-K 2021-03-31
2018 $44.5M +$25.7M +136% Feb 1, 2018 Jan 31, 2019 10-K 2021-03-31
2017 $18.8M Feb 1, 2017 Jan 31, 2018 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.